Transcranial Photobiomodulation: Can Red and Near-Infrared Light Improve Brain Health and Sleep?

Transcranial photobiomodulation (tPBM) is the application of specific wavelengths of red and near-infrared (NIR) light to the scalp and skull, with the goal of influencing brain tissue. The prefix "transcranial" means through the skull. The light is delivered non-invasively from an external device, passes through scalp and bone, and reaches the cerebral cortex and deeper brain structures.

Unlike laser-based neurostimulation or pharmaceutical interventions, tPBM works through photochemical mechanisms rather than heat or electrical current. Light energy is absorbed by photoreceptors inside cells, triggering a cascade of biological responses that affect mitochondrial function, cerebral blood flow, and neural activity.

It belongs to the broader field of photobiomodulation (PBM), which applies light therapy across a range of biological tissues. The brain-specific application is sometimes called neuro-photobiomodulation.

tPBM shines specific wavelengths of light through the skull to reach the brain. It does not use heat or electrical stimulation. It works by triggering natural cellular responses to light, primarily inside mitochondria.

Standard red light therapy targets skin, muscle, and superficial connective tissue. Devices used for joints, wounds, or skin are typically optimised for penetration depths of a few millimetres to a couple of centimetres.

Transcranial photobiomodulation is designed specifically to penetrate the skull. This requires wavelengths in the near-infrared range, typically 810nm to 1064nm, which scatter and absorb less in biological tissue than shorter visible red wavelengths. Device parameters, treatment sites, and dosing protocols for tPBM differ significantly from standard red light therapy applications.

The mechanisms behind tPBM involve multiple simultaneous biological processes. Current research points to four primary pathways.

The primary photoacceptor for red and NIR light in mammalian cells is cytochrome c oxidase (CCO), an enzyme within the mitochondrial electron transport chain. When light photons are absorbed by CCO, the enzyme becomes more active, increasing the production of adenosine triphosphate (ATP), the cell's primary energy currency.

Neurons are among the most metabolically demanding cells in the body. Their function is tightly coupled to ATP availability. When mitochondrial activity increases in response to light, neurons have more energy available for signalling, repair, and maintenance. This is particularly relevant in conditions where mitochondrial dysfunction is implicated, including Alzheimer's disease and Parkinson's disease.

Mitochondria are the brain's power generators. tPBM activates a key enzyme inside them, helping neurons produce more energy. More energy means better signalling, faster repair, and greater resilience, especially in brains where energy production has already declined.

tPBM influences nitric oxide (NO) signalling, which plays a central role in vascular tone. One proposed mechanism involves photodissociation: NIR light can displace nitric oxide from CCO, releasing it into surrounding tissue. Nitric oxide causes vasodilation of blood vessels, which improves regional cerebral blood flow.

Several human studies have measured increased cerebral oxygenation and blood flow following tPBM sessions. Better perfusion means more oxygen and glucose delivery to neural tissue, which supports cognitive performance and may help clear metabolic waste products, including amyloid beta in the context of Alzheimer's research.

tPBM causes blood vessels in the brain to relax and widen, improving circulation. More blood flow means more oxygen reaching neurons, and better clearance of the waste products that accumulate in aging and neurodegenerative disease.

Chronic neuroinflammation underlies many neurodegenerative conditions. Activated microglia and elevated pro-inflammatory cytokines create an environment hostile to neuronal health. Photobiomodulation has been shown in preclinical models to shift microglia from a pro-inflammatory (M1) phenotype toward an anti-inflammatory (M2) state.

tPBM also modulates reactive oxygen species (ROS). At low levels, ROS serve as signalling molecules. At elevated levels, they cause oxidative damage to neurons. Research suggests that appropriate PBM dosing can reduce excess ROS production while supporting beneficial redox signalling, creating a more neuroprotective cellular environment.

Inflammation in the brain damages neurons over time. tPBM appears to calm the immune cells responsible for this damage while also reducing chemical stress on brain cells. Think of it as switching the brain's immune response from high alert toward a lower-level maintenance mode.

Beyond cellular-level effects, tPBM appears to influence brain network activity. Electroencephalography (EEG) studies have recorded changes in alpha, beta, and gamma oscillations following transcranial light application. Functional MRI research has shown altered activity in the default mode network (DMN), which is involved in self-referential thought, memory consolidation, and cognitive baseline function.

Pulsed light delivery at specific frequencies, particularly 10Hz and 40Hz, may entrain corresponding brain oscillation patterns. This frequency-specific approach is an active area of investigation in Alzheimer's and ADHD research.

tPBM does not just affect individual cells. It appears to change the patterns of coordinated activity across brain networks. When light is pulsed at specific rhythms, it may nudge the brain toward oscillation patterns associated with focus, memory, or repair.

Sleep is not passive downtime for the brain. It is an active biological process that drives several functions critical to long-term brain health.

During deep non-REM sleep, the glymphatic system activates. This waste-clearance network flushes cerebrospinal fluid through the brain, removing metabolic byproducts including amyloid beta and tau, both of which are central to Alzheimer's pathology. Glymphatic clearance is substantially reduced during waking hours and impaired sleep, which is why chronic sleep disruption is now considered a risk factor for neurodegeneration rather than just a symptom of it.

Sleep also regulates neuroinflammation. Inflammatory markers including interleukin-6 and TNF-alpha rise with sleep deprivation and fall with restorative sleep. Mitochondrial recovery occurs during sleep as well, with neurons replenishing ATP stores and clearing oxidative stress accumulated during waking metabolic activity. Memory consolidation depends on sleep-stage-specific replay of neural patterns from the hippocampus to the cortex, a process disrupted by fragmented sleep architecture.

The relationship between sleep and neurodegenerative disease runs in both directions. Poor sleep accelerates pathology, and pathology disrupts sleep. This bidirectional loop is why sleep disturbance often appears years before a formal Alzheimer's or Parkinson's diagnosis.

For tPBM specifically, this connection matters because several of its proposed mechanisms, including mitochondrial support, reduced neuroinflammation, and improved cerebral blood flow, directly overlap with the biological processes that sleep depends on and supports.

These overlapping relationships are why tPBM is being investigated for sleep, cognitive performance, and neurodegeneration as a unified research area rather than three separate ones.

Because sleep impairment often precedes cognitive symptoms by several years, researchers increasingly view sleep optimization as a potential target for preserving long-term brain health. 

The brain's energy demands do not switch off during sleep. During non-REM slow-wave sleep, the brain undergoes energy replenishment processes, including restoration of glycogen stores and reduction of metabolic waste. Any intervention that supports mitochondrial efficiency may plausibly support the quality of restorative sleep stages.

The hypothesis is that better-energised neurons transition more efficiently into slow-wave sleep and sustain deeper sleep stages for longer. Direct evidence linking tPBM to slow-wave sleep enhancement in humans is limited but emerging.

Deep sleep is when the brain restores itself. If tPBM helps neurons produce more energy during waking hours, those neurons may enter the restorative phases of sleep more efficiently, where repair and waste clearance happen.

Circadian rhythm is regulated primarily by the suprachiasmatic nucleus (SCN) in the hypothalamus, which responds to environmental light signals. Blue and white light exposure in the evening suppresses melatonin production and delays sleep onset. Red and near-infrared light in the 630nm to 850nm range does not significantly stimulate the melanopsin receptors responsible for circadian disruption.

This means tPBM devices emitting in the red and NIR range are unlikely to suppress melatonin when used in the evening, which is an important practical consideration for sleep-focused applications. Some research suggests that evening red light exposure may support melatonin production, though the evidence for this remains preliminary.

Screens and bright white lights disrupt sleep by suppressing melatonin. Red and near-infrared light does not trigger the same response. That makes tPBM a circadian-safe option for evening use, and potentially a light exposure that actively supports the shift toward sleep.

For a broader look at how different light wavelengths interact with sleep biology, see our guide to what colour light helps you sleep.

A 2019 randomized controlled trial by Zhao and colleagues, published in the Journal of Athletic Training, examined female basketball athletes receiving 30 minutes of full-body red light exposure per night. Participants showed significant improvements in sleep quality measured by the Pittsburgh Sleep Quality Index, alongside increases in serum melatonin levels. While this was whole-body rather than transcranial application, it highlights a plausible relationship between PBM and sleep quality that has since prompted transcranial-specific investigation.

Studies targeting the prefrontal cortex and fronto-temporal regions have reported subjective improvements in sleep quality as secondary outcomes. Participants in some cognitive tPBM trials report falling asleep more easily, fewer nocturnal awakenings, and improved morning alertness. These are self-reported secondary findings rather than primary sleep endpoints, but the consistency across unrelated trials is worth noting. Large-scale sleep-specific tPBM trials are still underway, so the sleep evidence is best described as directionally positive rather than definitive.

For a deeper look at how portable devices fit into a sleep routine, see how portable red light therapy can improve sleep.

Heart rate variability is a marker of autonomic nervous system balance and is closely associated with sleep quality and recovery. Higher HRV during sleep indicates parasympathetic dominance, which corresponds to restorative rest. Preliminary research suggests PBM may support autonomic regulation, potentially via nitric oxide-mediated effects on vascular tone and vagal activity.

HRV is a measure of how well your nervous system is recovering during sleep. A higher HRV reading generally means deeper, more restorative rest. Some early research suggests PBM may support the shift toward the calmer nervous system state associated with quality sleep.

The relationship between tPBM, HRV, and sleep quality is an emerging area without large-scale confirmatory trials. See our full article on red light therapy for sleep and HRV for more detail.

Healing does not begin and end at the clinic. It is shaped by the daily choices that create an environment where recovery can thrive. Transcranial photobiomodulation can play a central role in that process, especially when used as part of a thoughtful routine.

Multiple studies using healthy adult populations have reported improvements in reaction time, working memory, and executive function following tPBM sessions targeting the prefrontal cortex. A 2017 study by Barrett and colleagues, published in Photonics, using 1064nm light reported significant improvement in sustained attention tasks compared to sham controls. The prefrontal cortex governs planning, decision-making, and inhibitory control, and its high metabolic demand makes it a plausible target for mitochondria-supporting interventions.

Cognitive fatigue involves a reduction in neural resource availability over time. Because tPBM may increase ATP production in neural tissue, researchers have proposed it as a potential strategy for mental fatigue recovery. Some protocols have explored pre-task light application as a method of increasing available brain energy before cognitively demanding work. This application remains preliminary but aligns directly with the underlying mechanism of mitochondrial stimulation.

Pilot studies have examined tPBM as a potential adjunct for depression. Research from the Schiffer group at McLean Hospital used NIR light applied to the forehead and reported reduced depressive symptoms in participants with major depressive disorder. The mechanisms likely involve prefrontal cortex stimulation and potentially modulation of monoaminergic pathways, though direct evidence for the latter is limited. These findings require replication in larger randomised controlled trials. Explore the full evidence in our article on red light therapy for depression.

Age-related cognitive decline is associated with mitochondrial dysfunction, reduced cerebral blood flow, and increased neuroinflammation. Each of these represents a potential target for tPBM. Researchers are investigating whether regular tPBM sessions over extended periods can support cognitive resilience in older adults. Current evidence is mostly from small pilot studies, and longer-term trials with standardised protocols are needed.

Early studies suggest that prefrontal tPBM may influence attention, processing speed, and executive function by supporting mitochondrial activity and cerebral blood flow in regions commonly implicated in ADHD. EEG recordings post-tPBM show changes in frontal beta and theta oscillations that partially overlap with the neural signatures associated with attentional control.

Most published studies involve fewer than 30 participants and use variable protocols. A 2021 review by Salehpour and colleagues identified tPBM as a promising but under-researched area for cognitive disorders, noting the need for standardised dosing and larger samples. tPBM is not a replacement for established ADHD treatments and is being investigated as a potential complementary approach rather than a standalone intervention.

Our article on red light therapy for ADHD covers the current evidence in more depth.

Alzheimer's disease involves mitochondrial dysfunction, neuroinflammation, reduced cerebral blood flow, and impaired glymphatic clearance, all of which are candidate targets for tPBM. Pilot studies in mild-to-moderate Alzheimer's populations have reported improvements in MMSE and ADAS-Cog cognitive assessment scores following repeated sessions. A 2021 study by Blivet and colleagues in an animal model showed reduced amyloid plaque burden following NIR light exposure, though translation from animal to human findings requires caution.

The 40Hz pulsed stimulation approach is a particularly active area of investigation, with research from the Tsai lab at MIT demonstrating that 40Hz sensory stimulation reduced amyloid and tau pathology and promoted microglial clearance in mouse models. Phase 2 clinical trials in human Alzheimer's populations are ongoing. This is not a proven treatment, but the mechanistic rationale is strong and the early clinical findings are encouraging.

For the glymphatic clearance angle, see our article on red light therapy for lymphatic drainage and glymphatics. For the full clinical picture, see red light therapy for Alzheimer's: what science says.

Parkinson's disease involves the progressive loss of dopaminergic neurons in the substantia nigra. Mitochondrial Complex I dysfunction in those neurons is well-documented, which creates a strong mechanistic rationale for tPBM investigation. Studies using NIR wavelengths including 670nm and 810nm have reported improvements in gait, balance, fine motor tasks, mood, and sleep in small Parkinson's cohorts. Animal studies have shown that NIR light can partially protect dopaminergic neurons from neurotoxic challenge.

John Mitrofanis and research teams in Australia have contributed substantially to the preclinical and early clinical evidence base. As with Alzheimer's research, findings are promising but require larger randomised trials with standardised protocols before firm conclusions can be drawn.

See our article on red light therapy for Parkinson's and what 670nm does to the brain for detailed coverage of the clinical research.

The wavelength and frequency parameters of a tPBM protocol determine how deeply light penetrates tissue and which cellular mechanisms are activated. Several wavelengths have emerged as particularly relevant for brain applications.

Not all wavelengths penetrate the brain equally. Different wavelengths and pulse frequencies are being investigated for different therapeutic goals, from cognitive performance and sleep support to neurodegenerative disease research. 

For a detailed breakdown of brain-specific wavelength research, see our guide to red light therapy Hz and wavelengths for brain health.

660nm sits at the red end of the visible spectrum. It is well-studied for skin and musculoskeletal applications but has limited skull penetration. Some tPBM protocols include 660nm alongside NIR wavelengths to address scalp tissue and improve vascular response at the surface, rather than for direct cortical effects.

810nm falls within a biological optical window where haemoglobin, water, and melanin absorb relatively little light, allowing greater penetration through scalp and skull. Studies by Naeser, Hamblin, and Saltmarche have used 810nm in clinical research on cognitive function and Alzheimer's disease. It is one of the most extensively studied and frequently cited wavelengths in tPBM research.

850nm shares similar CCO absorption properties to 810nm and is often paired with 660nm in commercial devices. Its penetration depth is comparable and its tissue absorption characteristics make it well-suited to cortical applications. Many studies examining cognitive and sleep outcomes have used 850nm either alone or in combination with other wavelengths.

904nm is typically delivered in pulsed rather than continuous wave mode. The pulsed nature may allow deeper tissue reach with lower average power and may influence cellular signalling differently from continuous delivery, though comparative evidence in brain applications is limited.

Studies by Gonzalez-Lima and colleagues at the University of Texas have used 1064nm to target prefrontal cortex activity, reporting improvements in memory, reaction time, and emotional regulation in human participants. At this wavelength, photons scatter less in biological tissue, potentially allowing deeper penetration toward subcortical structures. For a side-by-side analysis of the two longest research wavelengths, see 904nm vs 1064nm: which light reaches the brain.

When light is delivered in pulsed mode, the pulse frequency creates a temporal pattern of stimulation. Researchers have investigated whether pulsing at brain-relevant frequencies can entrain corresponding oscillation patterns.

Pulse Frequency Comparison: tPBM Research

40Hz pulsed stimulation has attracted particular attention in Alzheimer's research. Studies by the Tsai lab at MIT demonstrated that 40Hz sensory stimulation reduced amyloid and tau pathology in mouse models and promoted microglial clearance activity. 10Hz stimulation corresponds to alpha oscillation frequencies associated with relaxed alertness and attentional processing, and is being investigated for cognitive and mood applications.

Pulsing light at 10 or 40 times per second may encourage the brain to synchronise its own electrical rhythms to match. 40Hz is associated with memory processing and the clearance of Alzheimer's-related proteins. 10Hz is linked to calm, focused attention.

Based on available evidence, tPBM as used in clinical research protocols is generally well-tolerated. The approach is non-ionising and non-thermal at therapeutic doses, meaning it does not damage tissue through radiation or heat.

For a comprehensive safety overview covering dosing, contraindications, and evidence grading, see our red light therapy safety, dosage, and best practices guide.

Adverse effects reported in the literature are mild and infrequent. Some participants report temporary headache, mild scalp warmth, or transient fatigue following sessions. These effects have generally resolved without intervention. No serious adverse events have been attributed to tPBM in published clinical research to date.

Individuals with active malignancies should not receive light therapy over tumour sites without medical supervision. People with photosensitive conditions or those taking photosensitising medications should consult a healthcare provider before use. Those with implanted electrical devices such as deep brain stimulators should seek medical advice, as the interaction between tPBM and such devices has not been studied.

Pregnant individuals and those with active seizure disorders are typically excluded from research trials as a precautionary measure, and consumer use in these groups should follow medical guidance.

The tPBM field faces significant methodological challenges. Many studies use small sample sizes, lack convincingly blinded sham controls, and use heterogeneous protocols that make cross-study comparison difficult. The lack of standardised dosing guidelines means that research protocols differ substantially in wavelength, irradiance, pulse frequency, treatment duration, and site of application. This makes it difficult to determine whether commercial consumer devices replicate the conditions of research studies.

The mechanisms behind tPBM are grounded in established cellular biology: mitochondrial enzyme activation, improved cerebral blood flow, reduced neuroinflammation, and modulation of neural oscillations. These are documented phenomena, not speculative ones.

What remains to be established is how reliably these mechanisms translate into clinically meaningful outcomes across different populations, conditions, and device types. For sleep, the evidence is directionally positive and red and NIR light is at minimum circadian-safe. For cognitive performance in healthy adults, the findings are more developed. For ADHD, Alzheimer's, and Parkinson's, the research is mechanistically well-motivated and clinical trials are producing results that justify continued investigation.

The field needs standardisation: agreed dosing parameters, rigorous sham controls, longer follow-up periods, and larger samples. Even so, transcranial photobiomodulation has evolved from a niche research area into one of the fastest-growing fields in non-invasive brain health science. The next decade will likely determine whether tPBM becomes a practical tool for supporting sleep optimization, cognitive performance, and healthy brain aging.

This article is for educational purposes only. Transcranial photobiomodulation is not approved as a treatment for any medical condition. Consult a qualified healthcare provider before using any light therapy device for health purposes.

1. Red Light Therapy for Brain Health: Complete Hz & Wavelength Guide (10Hz–40Hz)
2. Red Light Therapy ADHD: What New Brain Research Reveals
3. Red Light Therapy for Alzheimer’s: What Science Says
4. Red Light Therapy for Parkinson's: What 670nm Actually Does to the Brain
5. 904nm vs 1064nm: Which Light Reaches the Brain?
6. Red Light Therapy Sleep: Improve Rest & HRV Naturally
7. What Color Light Helps You Sleep? (Red vs Blue Explained)
8. Red Light Therapy for Lymphatic Drainage: Glymphatics, Lymphedema, and What Studies Show

1. Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophysics. 2017;4(3):337-361.
2. Hamblin MR. Shining light on the head: Photobiomodulation for brain disorders. BBA Clinical. 2016;6:113-124.
3. Salehpour F, Cassano P, Rouhi N, et al. Penetration profiles of visible and near-infrared lasers and light-emitting diode light through the head and brain: A systematic review. Neurophotonics. 2019;6(1):011112.
4. Salehpour F, Mahmoudi J, Kamari F, Sadigh-Eteghad S, Rasta SH, Hamblin MR. Brain photobiomodulation therapy: A narrative review. Molecular Neurobiology. 2018;55(8):6601-6636.
5. Barrett DW, Gonzalez-Lima F. Transcranial infrared laser stimulation produces beneficial cognitive and emotional effects in humans. Neuroscience. 2013;230:13-23.
6. Gonzalez-Lima F, Barrett DW. Augmentation of cognitive brain functions with transcranial lasers. Frontiers in Systems Neuroscience. 2014;8:36.
7. Zhao J, Tian Y, Nie J, Xu J, Liu D. Red light and the sleep quality and endurance performance of Chinese female basketball players. Journal of Athletic Training. 2012;47(6):673-678.
8. Naeser MA, Saltmarche A, Krengel MH, et al. Improved cognitive function after transcranial, light-emitting diode treatments in chronic traumatic brain injury. Photomedicine and Laser Surgery. 2011;29(5):351-358.
9. Salehpour F, Gholipour-Khalili S, Farajdokht F, et al. Therapeutic potential of intranasal photobiomodulation therapy for neurological and neuropsychiatric disorders. European Journal of Neuroscience. 2020;51(1):441-458.
10. Mitrofanis J. Why and how does light therapy offer neuroprotection in Parkinson's disease? Neural Regeneration Research. 2017;12(4):574-575.
11. Cassano P, Petrie SR, Hamblin MR, et al. Review of transcranial photobiomodulation for major depressive disorder. Neurophotonics. 2016;3(3):031404.
12. Iaccarino HF, Singer AC, Martorell AJ, et al. Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature. 2016;540:230-235.
13. Blivet G, Meunier J, Roman FJ, et al. Neuroprotective effects of photobiomodulation in experimental models of Alzheimer's disease. Alzheimer's Research & Therapy. 2021.
14. Hablitz LM, Nedergaard M. The glymphatic system: A novel component of fundamental neurobiology. Journal of Neuroscience. 2021;41(37):7698-7711.
15. Chung H, Dai T, Sharma SK, Huang YY, Carroll JD, Hamblin MR. The nuts and bolts of low-level laser (light) therapy. Annals of Biomedical Engineering. 2012;40(2):516-533.